ClinicalTrials.gg
CompletedNCT03315130Updated Jul 27, 2022Results posted

Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

A Phase 2 interventional study of zilucoplan (RA101495) and Placebo in Generalized Myasthenia Gravis, sponsored by Ra Pharmaceuticals. Completed at 30 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-07-27.

Sponsored by Ra Pharmaceuticals (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Myasthenia Gravis by UCB S.A. — 5 open to participants now, 7 under way, 5 of them phase 3. Myasthenia Gravis · UCB S.A..

Enrollment
9th of 18
45 · median 45
Started
2017
with 1 other
Phase 2
2 of 18
none open now
Registered
2nd of 18
by date

Among the 18 studies in Myasthenia Gravis by UCB S.A., this one is the 9th largest by enrollment, is one of 2 that started in 2017, is one of 2 in phase 2, and was the 2nd registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

5 of the 18 studies in Myasthenia Gravis by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Myasthenia Gravis by UCB S.A., or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with generalized Myasthenia Gravis (gMG). Subjects will be randomized in a 1:1:1 ratio to receive daily SC doses of 0.1 mg/kg RA101495, 0.3 mg/kg RA101495, or matching placebo for 12 weeks.

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of gMG [Myasthenia Gravis Foundation of America (MGFA) Class II-IVa] at Screening
  • Positive serology for acetylcholine receptor (AChR) autoantibodies
  • QMG score ≥ 12 at Screening and Randomization
  • No change in dose for at least 30 days prior to Randomization or anticipated to occur during the 12-week Treatment Period
  • No change in therapy, including dose, for at least 30 days prior to Randomization or anticipated to occur during the 12-week Treatment Period

Exclusion criteria

Exclusion Criteria:

  • Thymectomy within 6 months prior to Randomization or scheduled to occur during the 12 week Treatment Period
  • History of meningococcal disease
  • Current or recent systemic infection within 2 weeks prior to Randomization or infection requiring intravenous (IV) antibiotics within 4 weeks prior to Randomization
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    0.1 mg/kg zilucoplan (RA101495)

    Drug: zilucoplan (RA101495)

  • Experimental
    0.3 mg/kg zilucoplan (RA101495)

    Drug: zilucoplan (RA101495)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Main Portion: Change From Baseline to Week 12 in Quantitative Myasthenia Gravis (QMG) Score

    The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for myasthenia gravis (MG). The scale consists of 13 individual assessments, each scored on a 0-3 point scale (i.e., 0=none, 1=mild, 2=moderate, and 3=severe). The total score is the sum of the individual scores with a range of 0-39. Higher scores are representative of more severe impairment.

    Time frame: From Baseline to Week 12

Secondary outcomes

  1. Main Portion: Change From Baseline to Week 12 in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Scale

    The MG-ADL is a brief 8-item survey designed to evaluate MG symptom severity. The scale consists of 8 items each scored on a 0-3 point scale (i.e., 0=none, 1=mild, 2=moderate, and 3=severe). The total score is the sum of the 8 individual scores with range of 0-24. Higher scores are associated with more severe symptoms of MG.

    Time frame: From Baseline to Week 12

  2. Main Portion: Change From Baseline to Week 12 in the Myasthenia Gravis - Quality of Life 15r (MG-QOL15r) Survey

    The MG-QOL15r is a 15-item survey that was designed to assess quality of life in participants with MG. The survey consisted of 15 questions and the corresponding responses were each scored on a 0-2 point scale (0=Not much at all, 1=Somewhat, 2=Very Much). The total score is the sum of the 15 individual item scores with a range of 0-30. Higher scores indicate more severe impact of the disease on aspects of the participant's life.

    Time frame: From Baseline to Week 12

  3. Main Portion: Change From Baseline to Week 12 in the MG Composite Scale Total Score

    The MG Composite is a 10-item scale that has been used to measure the clinical status of participants with MG, in order to evaluate treatment response. It consists of 10 items which included ptosis (score range=0 to 3), double vision on lateral gaze left/right/both (score range=0 to 4), eye closure (score range=0 to 2), talking (score range=0 to 6), chewing (score range=0 to 6), swallowing (score range=0 to 6), breathing (score range=0 to 9), neck flexion or extension (score range=0 to 4), shoulder abduction (score range=0 to 5) and hip flexion (score range= 0 to 5). The total score is the sum of the 10 individual scores with a range of 0-50. Higher scores in the MG Composite indicate more severe impairment due to the disease.

    Time frame: From Baseline to Week 12

  4. Main Portion: Percentage of Participants With >= 3-point Reduction in QMG Total Score at Week 12

    The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for MG. The scale consists of 13 individual assessments, each scored on a 0-3 point scale (i.e., 0=none, 1=mild, 2=moderate, and 3=severe). The total score is the sum of the individual scores with a range of 0-39. Higher scores are representative of more severe impairment.

    Time frame: Week 12

  5. Main Portion: Percentage of Participants Who Required Rescue Therapy Over the 12-week Treatment Period

    Percentage of participants who used at least 1 dose of rescue medication were reported.

    Time frame: Up to Week 12

  6. Main Portion: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulted in death, life-threatening, significant or persistent disability/incapacity, congenital anomaly/birth defect, important medical event, initial inpatient hospitalization or prolongation of hospitalization.

    Time frame: From Baseline to Week 12

  7. Main Portion: Change From Baseline in Sheep Red Blood Cell (sRBC) Lysis Assay at Week 12 (Pre-dose)

    A BioTek ELx800 automated microplate reader is used to measure the optical density at 415 nanometer (nm) of human plasma samples to calculate the percent lysis of sheep erythrocytes that has occurred as a result of total complement activity. The measure of complement activity is determined by the degree of hemolysis of the erythrocytes.

    Time frame: Baseline and Week 12 (Pre-dose)

  8. Main Portion: Change From Baseline in C5 Levels at Week 12 (Pre-dose)

    Blood samples were collected from participants to assess Complement Component 5C levels.

    Time frame: Baseline and Week 12 (Pre-dose)

  9. Main Portion: Plasma Concentration of RA101495 and Its Major Metabolites

    RA102758 and RA103488 are the metabolites of RA101495.

    Time frame: 1, 3 and 6 hours postdose on Day 1; Pre-dose on Week 1, 2, 4, 8 and 12

  10. Main Portion: Maximum Plasma Concentration (Cmax) on Day 1

    Cmax is defined as the maximum observed plasma concentration.

    Time frame: Pre-dose, 1, 3 and 6 hours postdose on Day 1

  11. Main Portion: Time Corresponding to Cmax (Tmax) on Day 1

    Tmax is defined as the time to observe maximum plasma concentration.

    Time frame: Pre-dose, 1, 3 and 6 hours postdose on Day 1

  12. Main Portion: Metabolites (RA102758 and RA103488) to Parent Ratio

    RA102758 and RA103488 are the metabolites of RA101495.

    Time frame: Pre-dose, 1, 3 and 6 hours postdose on Day 1; Pre-dose on Week 1, 2, 4, 8 and 12

07

Results

Posted Jun 27, 2022

Participant flow

The study started to enroll participants in October 2017 and concluded in November 2020.

Main Portion (12 Weeks)
Participant flow — Main Portion (12 Weeks)
MilestoneRA101495 0.1 mg/kgRA101495 0.3 mg/kgPlaceboRA101495 0.1 mg/kg (Before Switch) to 0.3 mg/kg (After Switch)
Started1515150
Completed1513150
Not completed0200
Withdrew: Subject withdrew consent0100
Withdrew: Lost to follow-up0100
EP:Before Switch to 0.3 mg/kg(Week13-48)
Participant flow — EP:Before Switch to 0.3 mg/kg(Week13-48)
MilestoneRA101495 0.1 mg/kgRA101495 0.3 mg/kgPlaceboRA101495 0.1 mg/kg (Before Switch) to 0.3 mg/kg (After Switch)
Started222100
Completed212100
Not completed1000
Withdrew: Subject withdrew consent1000
EP:After Switch to 0.3 mg/kg(Week48-122)
Participant flow — EP:After Switch to 0.3 mg/kg(Week48-122)
MilestoneRA101495 0.1 mg/kgRA101495 0.3 mg/kgPlaceboRA101495 0.1 mg/kg (Before Switch) to 0.3 mg/kg (After Switch)
Started021021
Completed017020
Not completed0401
Withdrew: Withdrawal by subject0100
Withdrew: Subject withdrew consent0100
Withdrew: Death0201

Outcome measures

PrimaryMain Portion: Change From Baseline to Week 12 in Quantitative Myasthenia Gravis (QMG) Score

The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for myasthenia gravis (MG). The scale consists of 13 individual assessments, each scored on a 0-3 point scale (i.e., 0=none, 1=mild, 2=moderate, and 3=severe). The total score is the sum of the individual scores with a range of 0-39. Higher scores are representative of more severe impairment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · score on a scale
Main Portion: Change From Baseline to Week 12 in Quantitative Myasthenia Gravis (QMG) Score
score on a scaleRA101495 0.1 mg/kg (mITT)RA101495 0.3 mg/kg (mITT)Placebo (mITT)
Main Portion: Change From Baseline to Week 12 in Quantitative Myasthenia Gravis (QMG) Score-5.5 ± 1.2-6.0 ± 1.2-3.2 ± 1.2
Statistical analysis
  • RA101495 0.1 mg/kg (mITT) vs Placebo (mITT) · ANCOVA · p = =0.0941 (1-sided p-value is presented for each active treatment arm compared to the Placebo treatment arm.) · Ls mean difference: -2.3 · 80% CI -4.5 to -0.1LS mean difference and associated confidence interval are presented for each active treatment arm compared to the Placebo treatment arm.
  • RA101495 0.3 mg/kg (mITT) vs Placebo (mITT) · ANCOVA · p = =0.0538 (1-sided p-value is presented for each active treatment arm compared to the Placebo treatment arm.) · Ls mean difference: -2.8 · 80% CI -5.1 to -0.6LS mean difference and associated confidence interval are presented for each active treatment arm compared to the Placebo treatment arm.
SecondaryMain Portion: Change From Baseline to Week 12 in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Scale

The MG-ADL is a brief 8-item survey designed to evaluate MG symptom severity. The scale consists of 8 items each scored on a 0-3 point scale (i.e., 0=none, 1=mild, 2=moderate, and 3=severe). The total score is the sum of the 8 individual scores with range of 0-24. Higher scores are associated with more severe symptoms of MG.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · score on a scale
Main Portion: Change From Baseline to Week 12 in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Scale
score on a scaleRA101495 0.1 mg/kg (mITT)RA101495 0.3 mg/kg (mITT)Placebo (mITT)
Main Portion: Change From Baseline to Week 12 in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Scale-3.3 ± 0.9-3.4 ± 0.9-1.1 ± 0.9
Statistical analysis
  • RA101495 0.1 mg/kg (mITT) vs Placebo (mITT) · ANCOVA · p = =0.0470 (1-sided p-value is presented for each active treatment arm compared to the Placebo treatment arm.) · Ls mean difference: -2.2 · 80% CI -3.9 to -0.5LS mean difference and associated confidence interval are presented for each active treatment arm compared to the Placebo treatment arm.
  • RA101495 0.3 mg/kg (mITT) vs Placebo (mITT) · ANCOVA · p = =0.0392 (1-sided p-value is presented for each active treatment arm compared to the Placebo treatment arm.) · Ls mean difference: -2.3 · 80% CI -4.0 to -0.6LS mean difference and associated confidence interval are presented for each active treatment arm compared to the Placebo treatment arm.
SecondaryMain Portion: Change From Baseline to Week 12 in the Myasthenia Gravis - Quality of Life 15r (MG-QOL15r) Survey

The MG-QOL15r is a 15-item survey that was designed to assess quality of life in participants with MG. The survey consisted of 15 questions and the corresponding responses were each scored on a 0-2 point scale (0=Not much at all, 1=Somewhat, 2=Very Much). The total score is the sum of the 15 individual item scores with a range of 0-30. Higher scores indicate more severe impact of the disease on aspects of the participant's life.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · score on a scale
Main Portion: Change From Baseline to Week 12 in the Myasthenia Gravis - Quality of Life 15r (MG-QOL15r) Survey
score on a scaleRA101495 0.1 mg/kg (mITT)RA101495 0.3 mg/kg (mITT)Placebo (mITT)
Main Portion: Change From Baseline to Week 12 in the Myasthenia Gravis - Quality of Life 15r (MG-QOL15r) Survey-7.4 ± 1.7-5.9 ± 1.7-2.1 ± 1.7
Statistical analysis
  • RA101495 0.1 mg/kg (mITT) vs Placebo (mITT) · ANCOVA · p = =0.0170 (1-sided p-value is presented for each active treatment arm compared to the Placebo treatment arm.) · Ls mean difference: -5.3 · 80% CI -8.4 to -2.1LS mean difference and associated confidence interval are presented for each active treatment arm compared to the Placebo treatment arm.
  • RA101495 0.3 mg/kg (mITT) vs Placebo (mITT) · ANCOVA · p = =0.0624 (1-sided p-value is presented for each active treatment arm compared to the Placebo treatment arm.) · Ls mean difference: -3.7 · 80% CI -6.9 to -0.6LS mean difference and associated confidence interval are presented for each active treatment arm compared to the Placebo treatment arm.
SecondaryMain Portion: Change From Baseline to Week 12 in the MG Composite Scale Total Score

The MG Composite is a 10-item scale that has been used to measure the clinical status of participants with MG, in order to evaluate treatment response. It consists of 10 items which included ptosis (score range=0 to 3), double vision on lateral gaze left/right/both (score range=0 to 4), eye closure (score range=0 to 2), talking (score range=0 to 6), chewing (score range=0 to 6), swallowing (score range=0 to 6), breathing (score range=0 to 9), neck flexion or extension (score range=0 to 4), shoulder abduction (score range=0 to 5) and hip flexion (score range= 0 to 5). The total score is the sum of the 10 individual scores with a range of 0-50. Higher scores in the MG Composite indicate more severe impairment due to the disease.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · score on a scale
Main Portion: Change From Baseline to Week 12 in the MG Composite Scale Total Score
score on a scaleRA101495 0.1 mg/kg (mITT)RA101495 0.3 mg/kg (mITT)Placebo (mITT)
Main Portion: Change From Baseline to Week 12 in the MG Composite Scale Total Score-5.3 ± 1.5-7.4 ± 1.6-3.3 ± 1.6
Statistical analysis
  • RA101495 0.1 mg/kg (mITT) vs Placebo (mITT) · ANCOVA · p = =0.1866 (1-sided p-value is presented for each active treatment arm compared to the Placebo treatment arm.) · Ls mean difference: -2.0 · 80% CI -4.9 to 0.9LS mean difference and associated confidence interval are presented for each active treatment arm compared to the Placebo treatment arm.
  • RA101495 0.3 mg/kg (mITT) vs Placebo (mITT) · ANCOVA · p = =0.0391 (1-sided p-value is presented for each active treatment arm compared to the Placebo treatment arm.) · Ls mean difference: -4.1 · 80% CI -7.0 to -1.1LS mean difference and associated confidence interval are presented for each active treatment arm compared to the Placebo treatment arm.
SecondaryMain Portion: Percentage of Participants With >= 3-point Reduction in QMG Total Score at Week 12

The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for MG. The scale consists of 13 individual assessments, each scored on a 0-3 point scale (i.e., 0=none, 1=mild, 2=moderate, and 3=severe). The total score is the sum of the individual scores with a range of 0-39. Higher scores are representative of more severe impairment.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Main Portion: Percentage of Participants With >= 3-point Reduction in QMG Total Score at Week 12
percentage of participantsRA101495 0.1 mg/kg (mITT)RA101495 0.3 mg/kg (mITT)Placebo (mITT)
Main Portion: Percentage of Participants With >= 3-point Reduction in QMG Total Score at Week 1266.771.453.3
SecondaryMain Portion: Percentage of Participants Who Required Rescue Therapy Over the 12-week Treatment Period

Percentage of participants who used at least 1 dose of rescue medication were reported.

Time frame:
Up to Week 12
Reported as:
Number · percentage of participants
Main Portion: Percentage of Participants Who Required Rescue Therapy Over the 12-week Treatment Period
percentage of participantsRA101495 0.1 mg/kg (mITT)RA101495 0.3 mg/kg (mITT)Placebo (mITT)
Main Portion: Percentage of Participants Who Required Rescue Therapy Over the 12-week Treatment Period6.7020.0
SecondaryMain Portion: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulted in death, life-threatening, significant or persistent disability/incapacity, congenital anomaly/birth defect, important medical event, initial inpatient hospitalization or prolongation of hospitalization.

Time frame:
From Baseline to Week 12
Reported as:
Count of participants · Participants
Main Portion: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsRA101495 0.1 mg/kg (SS)RA101495 0.3 mg/kg (SS)Placebo (SS)
AEs151214
SAEs053
SecondaryMain Portion: Change From Baseline in Sheep Red Blood Cell (sRBC) Lysis Assay at Week 12 (Pre-dose)

A BioTek ELx800 automated microplate reader is used to measure the optical density at 415 nanometer (nm) of human plasma samples to calculate the percent lysis of sheep erythrocytes that has occurred as a result of total complement activity. The measure of complement activity is determined by the degree of hemolysis of the erythrocytes.

Time frame:
Baseline and Week 12 (Pre-dose)
Reported as:
Least squares mean · percent lysis of sheep erythrocytes
Main Portion: Change From Baseline in Sheep Red Blood Cell (sRBC) Lysis Assay at Week 12 (Pre-dose)
percent lysis of sheep erythrocytesRA101495 0.1 mg/kg (PD)RA101495 0.3 mg/kg (PD)Placebo (PD)
Main Portion: Change From Baseline in Sheep Red Blood Cell (sRBC) Lysis Assay at Week 12 (Pre-dose)-81.822 ± 2.469-94.914 ± 2.9080.775 ± 2.571
Statistical analysis
  • RA101495 0.1 mg/kg (PD) vs Placebo (PD) · ANCOVA · p = <0.0001 (1-sided p-value is presented for each active treatment arm compared to the Placebo treatment arm.) · Ls mean difference: -82.597 · 80% CI -87.249 to -77.946LS mean difference and associated confidence interval are presented for each active treatment arm compared to the Placebo treatment arm.
  • RA101495 0.3 mg/kg (PD) vs Placebo (PD) · ANCOVA · p = <0.0001 (1-sided p-value is presented for each active treatment arm compared to the Placebo treatment arm.) · Ls mean difference: -95.689 · 80% CI -100.794 to -90.585LS mean difference and associated confidence interval are presented for each active treatment arm compared to the Placebo treatment arm.
SecondaryMain Portion: Change From Baseline in C5 Levels at Week 12 (Pre-dose)

Blood samples were collected from participants to assess Complement Component 5C levels.

Time frame:
Baseline and Week 12 (Pre-dose)
Reported as:
Least squares mean · micrograms/milliliter (ug/mL)
Main Portion: Change From Baseline in C5 Levels at Week 12 (Pre-dose)
micrograms/milliliter (ug/mL)RA101495 0.1 mg/kg (PD)RA101495 0.3 mg/kg (PD)Placebo (PD)
Main Portion: Change From Baseline in C5 Levels at Week 12 (Pre-dose)57.349 ± 7.05754.302 ± 6.804-2.774 ± 6.237
Statistical analysis
  • RA101495 0.1 mg/kg (PD) vs Placebo (PD) · ANCOVA · p = <0.0001 (1-sided p-value is presented for each active treatment arm compared to the Placebo treatment arm.) · Ls mean difference: 60.123 · 80% CI 47.839 to 72.408LS mean difference and associated confidence interval are presented for each active treatment arm compared to the Placebo treatment arm.
  • RA101495 0.3 mg/kg (PD) vs Placebo (PD) · ANCOVA · p = <0.0001 (1-sided p-value is presented for each active treatment arm compared to the Placebo treatment arm.) · Ls mean difference: 57.076 · 80% CI 44.955 to 69.197LS mean difference and associated confidence interval are presented for each active treatment arm compared to the Placebo treatment arm.
SecondaryMain Portion: Plasma Concentration of RA101495 and Its Major Metabolites

RA102758 and RA103488 are the metabolites of RA101495.

Time frame:
1, 3 and 6 hours postdose on Day 1; Pre-dose on Week 1, 2, 4, 8 and 12
Reported as:
Mean · nanograms/milliliter (ng/mL)
Main Portion: Plasma Concentration of RA101495 and Its Major Metabolites
nanograms/milliliter (ng/mL)RA101495 0.1 mg/kg (PK)RA101495 0.3 mg/kg (PK)
RA101495- Day 1: 1 hour postdose652.136 ± 354.6522272.257 ± 1246.128
RA101495- Day 1: 3 hours postdose1691.267 ± 469.7664176.000 ± 1211.166
RA101495- Day 1: 6 hours postdose1925.357 ± 330.3354636.000 ± 809.804
RA101495- Week 1: Pre-dose4571.214 ± 719.5669223.786 ± 2365.168
RA101495- Week 2: Pre-dose4914.200 ± 743.21510222.846 ± 1662.869
RA101495- Week 4: Pre-dose5100.286 ± 859.76710265.917 ± 1604.004
RA101495- Week 8: Pre-dose5222.067 ± 688.42710075.000 ± 1872.400
RA101495- Week 12: Pre-dose5281.333 ± 1122.37210284.846 ± 1771.586
RA102758- Day 1: 1 hour postdoseNA ± NANA ± NA
RA102758- Day 1: 3 hours postdoseNA ± NANA ± NA
RA102758- Day 1: 6 hours postdoseNA ± NANA ± NA
RA102758- Week 1: Pre-dose252.693 ± 78.909849.743 ± 273.388
RA102758- Week 2: Pre-dose408.847 ± 94.7731473.431 ± 440.496
RA102758- Week 4: Pre-dose462.486 ± 180.0981567.692 ± 557.745
RA102758- Week 8: Pre-dose474.073 ± 157.5491432.808 ± 530.377
RA102758- Week 12: Pre-dose465.665 ± 195.2271459.062 ± 451.013
RA103488- Day 1: 1 hour postdoseNA ± NANA ± NA
RA103488- Day 1: 3 hours postdoseNA ± NANA ± NA
RA103488- Day 1: 6 hours postdoseNA ± NA85.832 ± 257.664
RA103488- Week 1: Pre-dose356.186 ± 162.209838.907 ± 255.419
RA103488- Week 2: Pre-dose501.847 ± 218.4671135.731 ± 270.004
RA103488- Week 4: Pre-dose536.266 ± 275.0131191.783 ± 251.853
RA103488- Week 8: Pre-dose615.740 ± 229.3591234.708 ± 201.055
RA103488- Week 12: Pre-dose621.813 ± 241.3541307.492 ± 331.553
SecondaryMain Portion: Maximum Plasma Concentration (Cmax) on Day 1

Cmax is defined as the maximum observed plasma concentration.

Time frame:
Pre-dose, 1, 3 and 6 hours postdose on Day 1
Reported as:
Mean · ng/mL
Main Portion: Maximum Plasma Concentration (Cmax) on Day 1
ng/mLRA101495 0.1 mg/kg (PK)RA101495 0.3 mg/kg (PK)
Main Portion: Maximum Plasma Concentration (Cmax) on Day 11945.467 ± 407.2734858.643 ± 1004.457
SecondaryMain Portion: Time Corresponding to Cmax (Tmax) on Day 1

Tmax is defined as the time to observe maximum plasma concentration.

Time frame:
Pre-dose, 1, 3 and 6 hours postdose on Day 1
Reported as:
Median · hours
Main Portion: Time Corresponding to Cmax (Tmax) on Day 1
hoursRA101495 0.1 mg/kg (PK)RA101495 0.3 mg/kg (PK)
Main Portion: Time Corresponding to Cmax (Tmax) on Day 14.550 (2.95 to 5.50)4.700 (2.62 to 5.92)
SecondaryMain Portion: Metabolites (RA102758 and RA103488) to Parent Ratio

RA102758 and RA103488 are the metabolites of RA101495.

Time frame:
Pre-dose, 1, 3 and 6 hours postdose on Day 1; Pre-dose on Week 1, 2, 4, 8 and 12
Reported as:
Mean · ratio
Main Portion: Metabolites (RA102758 and RA103488) to Parent Ratio
ratioRA101495 0.1 mg/kg (PK)RA101495 0.3 mg/kg (PK)
RA102758/RA101495- Day 1: Pre-doseNA ± NANA ± NA
RA102758/RA101495- Day 1: 1 hour postdose0.000 ± 0.0000.000 ± 0.000
RA102758/RA101495- Day 1: 3 hours postdose0.000 ± 0.0000.000 ± 0.000
RA102758/RA101495- Day 1: 6 hours postdose0.000 ± 0.0000.013 ± 0.044
RA102758/RA101495- Week 1: Pre-dose0.121 ± 0.0330.202 ± 0.038
RA102758/RA101495- Week 2: Pre-dose0.182 ± 0.0380.307 ± 0.057
RA102758/RA101495- Week 4: Pre-dose0.197 ± 0.0720.323 ± 0.072
RA102758/RA101495- Week 8: Pre-dose0.195 ± 0.0570.301 ± 0.070
RA102758/RA101495- Week 12: Pre-dose0.184 ± 0.0650.303 ± 0.061
RA103488/RA101495- Day 1: Pre-doseNA ± NANA ± NA
RA103488/RA101495- Day 1: 1 hour postdose0.000 ± 0.0000.000 ± 0.000
RA103488/RA101495- Day 1: 3 hours postdose0.000 ± 0.0000.001 ± 0.001
RA103488/RA101495- Day 1: 6 hours postdose0.000 ± 0.0000.015 ± 0.045
RA103488/RA101495- Week 1: Pre-dose0.079 ± 0.0370.099 ± 0.044
RA103488/RA101495- Week 2: Pre-dose0.104 ± 0.0440.114 ± 0.037
RA103488/RA101495- Week 4: Pre-dose0.106 ± 0.0460.119 ± 0.038
RA103488/RA101495- Week 8: Pre-dose0.118 ± 0.0440.127 ± 0.040
RA103488/RA101495- Week 12: Pre-dose0.116 ± 0.0350.131 ± 0.041

Adverse events

Collected over From Baseline up to Week 122. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Portion: RA101495 0.1 mg/kg0/15 (0%)0/15 (0%)15/15 (100%)
Main Portion: RA101495 0.3 mg/kg0/14 (0%)5/14 (35.7%)12/14 (85.7%)
Main Portion: Placebo0/15 (0%)3/15 (20%)14/15 (93.3%)
Main and Extension Portion: RA101495 0.1 mg/kg Before Switch to 0.3 mg/kg1/22 (4.5%)5/22 (22.7%)22/22 (100%)
Main and Extension Portion: RA101495 0.1 mg/kg After Switch to 0.3 mg/kg0/21 (0%)4/21 (19%)17/21 (81%)
Main and Extension Portion: RA101495 0.3 mg/kg2/21 (9.5%)11/21 (52.4%)21/21 (100%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventMain Portion: RA101495 0.1 mg/kgMain Portion: RA101495 0.3 mg/kgMain Portion: PlaceboMain and Extension Portion: RA101495 0.1 mg/kg Before Switch to 0.3 mg/kgMain and Extension Portion: RA101495 0.1 mg/kg After Switch to 0.3 mg/kgMain and Extension Portion: RA101495 0.3 mg/kg
Worsening of Myasthenia GravisNervous system disorders0/150/143/150/220/210/21
Pancreas infectionInfections and infestations0/150/140/150/220/212/21
Post procedural complicationInjury, poisoning and procedural complications0/150/140/150/220/212/21
CholecystitisHepatobiliary disorders0/150/140/150/220/212/21
PneumoniaInfections and infestations0/150/140/152/221/211/21
CellulitisInfections and infestations0/151/140/150/220/211/21
Abdominal abscessInfections and infestations0/151/140/150/220/211/21
DiverticulitisInfections and infestations0/151/140/150/220/211/21
Systemic inflammatory response syndromeGeneral disorders0/151/140/150/220/211/21
Blood culture positiveInvestigations0/151/140/150/220/211/21
Most frequent other events
Showing 10 of 113
Most frequent other events
EventMain Portion: RA101495 0.1 mg/kgMain Portion: RA101495 0.3 mg/kgMain Portion: PlaceboMain and Extension Portion: RA101495 0.1 mg/kg Before Switch to 0.3 mg/kgMain and Extension Portion: RA101495 0.1 mg/kg After Switch to 0.3 mg/kgMain and Extension Portion: RA101495 0.3 mg/kg
HeadacheNervous system disorders6/153/144/1510/223/214/21
NasopharyngitisInfections and infestations1/150/140/156/225/218/21
Injection site bruisingGeneral disorders2/150/142/156/220/213/21
DizzinessNervous system disorders1/150/144/154/223/213/21
Back painMusculoskeletal and connective tissue disorders1/151/141/152/220/215/21
NauseaGastrointestinal disorders2/150/140/154/221/215/21
DiarrhoeaGastrointestinal disorders1/151/141/152/220/215/21
CoughRespiratory, thoracic and mediastinal disorders0/150/140/153/221/215/21
Injection site scabGeneral disorders3/150/140/153/220/210/21
Upper respiratory tract infectionInfections and infestations0/150/140/153/222/214/21

Baseline characteristics

Intent-to-Treat (ITT) population included all randomized participants.

Age, Categorical
Age, Categorical(Participants)RA101495 0.1 mg/kgRA101495 0.3 mg/kgPlaceboTotal
<=18 years0000
Between 18 and 65 years14111338
>=65 years1427
Age, Continuous
Age, Continuous(years)RA101495 0.1 mg/kgRA101495 0.3 mg/kgPlaceboTotal
Mean45.5 ± 15.654.5 ± 14.948.4 ± 15.749.5 ± 15.5
Sex: Female, Male
Sex: Female, Male(Participants)RA101495 0.1 mg/kgRA101495 0.3 mg/kgPlaceboTotal
Female851124
Male710421
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RA101495 0.1 mg/kgRA101495 0.3 mg/kgPlaceboTotal
Asian0112
Black or African American2327
White13111236
08

Study locations

30 sites
  • Diagnostic and Medical Clinic - Mobile
    Mobile, Alabama 36604, United States
  • The Research Center of Southern California
    Carlsbad, California 92011, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • University of California Irvine Health ALS and Neuromuscular Center
    Orange, California 92868, United States
  • Yale University
    New Haven, Connecticut 06520, United States
  • George Washington University
    Washington, District of Columbia 20052, United States
  • University of Florida
    Jacksonville, Florida 32209, United States
  • University of South Florida
    Tampa, Florida 33620, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Lahey Hospital and Medical Center
    Burlington, Massachusetts 01805, United States
  • Wayne State University
    Detroit, Michigan 48202, United States
  • Michigan State University
    East Lansing, Michigan 48864, United States
  • University of Buffalo
    Buffalo, New York 14260, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Allegheny Neurological Associates
    Pittsburgh, Pennsylvania 15212, United States
  • Wesley Neurology Clinic
    Cordova, Tennessee 38018, United States
  • University of Texas Southwestern
    Dallas, Texas 75390, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • University of Vermont
    Burlington, Vermont 05405, United States
  • Center for Neurological Disorders
    Milwaukee, Wisconsin 53215, United States
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • London Health Sciences Centre University Hospital
    London, Ontario N6A 5A5, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Montreal Neurological Institute and Hospital
    Montreal, Quebec H3A 2B4, Canada
09

References and documents

Publications

  • Howard JF Jr, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ; Zilucoplan MG Study Group; Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar MG, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson S, Janecki T, Freimer M, Elsheikh B, Matisak P, Genge A, Guidon A, David W, Habib AA, Mathew V, Mozaffar T, Hinton JL, Hewitt W, Barnett D, Sullivan P, Ho D, Howard JF Jr, Traub RE, Chopra M, Kaminski HJ, Aly R, Bayat E, Abu-Rub M, Khan S, Lange D, Holzberg S, Khatri B, Lindman E, Olapo T, Sershon LM, Lisak RP, Bernitsas E, Jia K, Malik R, Lewis-Collins TD, Nicolle M, Nowak RJ, Sharma A, Roy B, Nye J, Pulley M, Berger A, Shabbir Y, Sachdev A, Patterson K, Siddiqi Z, Sivak M, Bratton J, Small G, Kohli A, Fetter M, Vu T, Lam L, Harvey B, Wolfe GI, Silvestri N, Patrick K, Zakalik K, Duda PW, MacDougall J, Farzaneh-Far R, Pontius A, Hoarty M. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol. 2020 May 1;77(5):582-592. doi: 10.1001/jamaneurol.2019.5125. PubMed 32065623 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Dec 2018, 13 months.

Results were first posted in Jun 2022, 3 years 6 months after primary completion. A results delay was requested in Aug 2020.

Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2017
First posted
Oct 19, 2017
StartActual
Oct 11, 2017
Primary completionActual
Dec 10, 2018
CompletionActual
Nov 19, 2020
Results delay requested
Aug 25, 2020
Results first posted
Jun 27, 2022
Last update
Jul 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03315130
Lead sponsor
Ra Pharmaceuticals
Responsible party
Sponsor
First posted
Oct 19, 2017
Start date
Oct 11, 2017
Primary completion
Dec 10, 2018
Completion
Nov 19, 2020
Results posted
Jun 27, 2022
Last update
Jul 27, 2022

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zilucoplan

Start the discussion